← Browse by Condition
Medical Condition
acral lentiginous melanoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for acral lentiginous melanoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 1
Phase 2 1
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT03025256 Phase 1
Recruiting
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
Enrollment
75 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT04511013 Phase 2
Recruiting
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Enrollment
112 pts
Location
United States
Sponsor
SWOG Cancer Research Network
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology